Navigation Links
Repligen Announces Conference Call to Discuss Phase 3 Clinical Trial Results of RG1068 in MRI Imaging of the Pancreas
Date:12/8/2009

ditional information may be requested from www.repligen.com.

This press release contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements in this release do not constitute guarantees of future performance. Investors are cautioned that statements in this press release which are not strictly historical statements, including, without limitation, statements regarding current or future financial performance and position, management's strategy, plans and objectives for future operations, plans and objectives for product development, plans and objectives for present and future clinical trials and results of such trials, plans and objectives for regulatory approval, litigation, intellectual property, product development, manufacturing plans and performance such as the anticipated growth in the monoclonal antibody market and our other target markets and projected growth in product sales, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including, without limitation, risks associated with: the success of current and future collaborative relationships, the market acceptance of our products, our ability to compete with larger, better financed pharmaceutical and biotechnology companies, new approaches to the treatment of our targeted diseases, our expectation of incurring continued losses, our uncertainty of product revenues and profits, our ability to generate future revenues, our ability to raise additional capital to c
'/>"/>

SOURCE Repligen Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Repligen Announces Conference Call of Third Quarter Fiscal Year 2008 Results
2. Repligen Announces Settlement with Bristol-Myers Squibb in Orencia(R) Lawsuit
3. Repligen Reports Fourth Quarter and Fiscal Year 2008 Financial Results
4. Repligen Announces Conference Call of First Quarter Fiscal Year 2009 Results
5. Repligen Receives Research Grants to Support Friedreichs Ataxia Development Program
6. Repligen Announces Publication of Positive Results with Proprietary HDAC Inhibitor in Huntingtons Disease Model
7. Repligen to Present at the 2008 UBS Global Life Sciences Conference Wednesday, September 24th, 1:00 p.m. EDT
8. Repligen to Present at the Rodman & Renshaw 10th Annual Healthcare Conference Monday, November 10th, 4:55 p.m. EST
9. Repligen Announces Conference Call of Third Quarter Fiscal Year 2009 Results
10. Repligen to Present at the BIO CEO & Investor Conference Monday, February 9th, 11:30 a.m. EST
11. Repligen Reports Third Quarter Fiscal Year 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... ... 2015 , ... Since the initial launch of FireflySci Inc. (FFS) in early 2015, the company ... Images such as the Fonz in a lab coat and Large Marge have been ... spectroscopy field. , FireflySci is proud to be the only cuvette manufacturer is ...
(Date:8/27/2015)... Aug. 27, 2015 /PRNewswire/ - Portage Biotech Inc. ... and Biohaven Pharmaceutical Holding Company Limited (Biohaven), announced ... I study of BHV-0223, a glutamate modulating agent. ... BHV-0223 and recently obtained clearance from the U.S. ... human testing. Portage holds 54% equity interest in ...
(Date:8/27/2015)... , Aug. 27, 2015 HUYA Bioscience International ... of the Japan Society of HTLV-1, held this week ... The purpose of the Society is to promote research ... development of medical technology and research related to these ... "HUYA is proud to support this prestigious ...
(Date:8/27/2015)... , Aug. 27, 2015 In ... by FedEx, UPS and The US Postal Service ... specimens classified as ,select agents, by the CDC, ... of handling these sensitive shipments. Marken ... transportation regulations, trained and certified personnel to ensure ...
Breaking Biology Technology:Cuvette Manufacturer FireflySci Launches Back to School Deals with Complimentary Shipping On All Orders 2Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 2Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 4HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 2HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 3HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 4Marken Ensures Safe Transportation Of Select Agents And Toxins 2
... Vical Incorporated,(Nasdaq: VICL ) presentation at the ... at 1 p.m. Eastern Daylight Time, will be ... page at http://www.vical.com ., About Vical, ... on its,patented DNA delivery technologies for the prevention ...
... - Oncentra(R) RT Viewer* Officially to Launch ... ASTRO 2008, Boston, USA, September,21-24, Nucletron, a ... release of Oncentra RT Viewer. This unique innovation,in ... review,radiotherapy plans that are generated with a wide ...
... significant partial onset seizure reduction, proven ... - Keppra XR(TM) is ... press release, regulated information:,UCB announced today that the U.S. Food ... for use as,an add-on to other antiepileptic treatments for people ...
Cached Biology Technology:Vical to Present at UBS Global Life Sciences Conference 2Nucletron Announces Market Release of First Commercially Available Software to Review and Share Dicom-Based Treatment Plans for Radiotherapy 2Video: Keppra XR(TM) Approved in the U.S. 2Video: Keppra XR(TM) Approved in the U.S. 3Video: Keppra XR(TM) Approved in the U.S. 4
(Date:8/17/2015)... 2015  NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... the growing mobile commerce market and creator of the ... Q4 2015. The new marketing campaign is being spearheaded ... Marketing Group ( http://amplitudemarketing.com/ ) and TPMG ( http://tmpg.com/ ... in retail driven marketing and brand awareness and has ...
(Date:8/11/2015)... Today, ZUK announced its Android smartphone Z1, featuring FPC,s ... in 2015 that relate to sales of FPC1155 for this smartphone ... MSEK for 2015. Jörgen Lantto, CEO of FPC, comments: ... smartphone manufacturer in China and we are ... for Z1 , its ...
(Date:8/6/2015)... , Aug. 6, 2015 Synaptics ... of human interface solutions, today announced collaboration with ... on Windows 10. Microsoft leveraged Synaptics, deep expertise ... operating system. Through stringent testing, ... fully certified with Microsoft,s Precision TouchPad (PTP) specification ...
Breaking Biology News(10 mins):NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 2NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 3FPC's Touch Fingerprint Sensor FPC1155 in ZUK's Smartphone Z1 2Synaptics Chosen for Human Interface Co-Development on Windows 10 2
... Va.Rear Adm. Matthew Klunder, the chief of naval research, told ... science and technology (S&T) conference this week that he intends ... academia together on a quarterly basis, starting in 2013, to ... conference every two years, which is phenomenal and very valuableand ...
... , BioFrontiers Institute scientists at the University of Colorado Boulder, ... anti-cancer drug development that is sitting at the ends of ... collaborated to find a patch of amino acids that, if ... this location, may prevent cancerous cells from reproducing. The amino ...
... BEDFORD, Mass., Sept. 21, 2012 Aware, Inc. (NASDAQ: ... completed the sale (as previously announced on August 23, ... Delta, LLC for US $16,000,000.00.  The patents and patent ... of our patent management operation,s efforts to sell and/or ...
Cached Biology News:In an uncertain world, Navy needs science and technology collaboration, chief says 2CU-Boulder researchers uncover new target for cancer research 2Aware Announces Closing Of Sale Of Selected Patents 2Aware Announces Closing Of Sale Of Selected Patents 3